■尽管在非肌肉浸润性膀胱癌患者中制定了随访方案,无法预防进展和复发。
■我们旨在研究OCT-4、CD47、p53、Ki-67和Survivin等蛋白质膀胱癌细胞的增加,可作为非肌层浸润性膀胱癌患者的预后指标。
该研究纳入了2015年1月至2020年12月期间89例新诊断的非肌层浸润性膀胱癌患者。
■用半定量免疫组织化学实验测定癌细胞中OCT-4、CD47、p53、K-67和Survivin蛋白的水平。根据染色率比较病理数据和存活率。
■使用SPSS22.0(SPSS,芝加哥,IL,美国)。
■患者的平均年龄为64.25±9.91岁,中位随访期为55个月.复发率为36%(n=32),进展率为40.4%(n=36)。在进展组和晚期肿瘤中,每个标记物的染色率更强(p<0.001)。作为研究的一部分进行的多变量分析的结果表明,年龄较大和肿瘤分期较高是无复发生存的独立危险因素(HR分别为1.048和7.074;P=0.02)。此外,肿瘤分期较高,直径,和分级与无进展生存期降低相关(HR分别为0.105、0.395、0.225;P<0.05)。
■尽管免疫组织化学染色率很有希望,在评估非肌层浸润性膀胱癌患者的生存率时,更适合使用肿瘤特征.
UNASSIGNED: Despite the follow-up protocols developed in non-muscle-invasive bladder cancer patients, progression and recurrence could not be prevented.
UNASSIGNED: We aimed to investigate whether proteins such as OCT-4, CD47, p53, Ki-67, and Survivin, which increase in bladder cancer cells, can be used as prognostic markers for patients with non-muscle-invasive bladder cancer.
UNASSIGNED: The study included a total of 89 patients with newly diagnosed non-muscle-invasive bladder cancer between January 2015 and December 2020.
UNASSIGNED: Levels of OCT-4, CD47, p53, Kİ-67, and Survivin proteins in cancer cells were determined with a semi-quantitative immunohistochemical experiment. Pathological data and survival rates were compared according to the staining rates.
UNASSIGNED: Data obtained in the study were analyzed statistically with SPSS 22.0 (SPSS, Chicago, IL, USA).
UNASSIGNED: The mean age of the patients was 64.25 ± 9.91 years, and the median follow-up period was 55 months. Recurrence rate was determined to be 36% (n = 32), and the rate of progression at 40.4% (n = 36). The staining rates were stronger for each marker in the progression group and advanced-stage tumors (p < 0.001). The findings of the multivariate analysis carried out as part of the study showed that older age and higher tumor stage were independent risk factors for recurrence-free survival (HR = 1.048 and 7.074, respectively; P = 0.02). Also, higher tumor stages, diameters, and grades were associated with reduced progression-free survival (HR = 0.105, 0.395, 0.225, respectively; P < 0.05).
UNASSIGNED: Although immunohistochemical staining rates are promising, it is more appropriate to use tumor characteristics when assessing survival rate in patients with non-muscle-invasive bladder cancer.